Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Pancreatic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Lung Neoplasms 2Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Thrombocythemia, Essential 1Prostatic Neoplasms 1Primary Myelofibrosis 1Polycythemia Vera 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1Neuroendocrine Tumors 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Accelerated Phase 1Kidney Neoplasms 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms, Male 1Breast Neoplasms 1Blast Crisis 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1Adenocarcinoma Of Esophagus 1

Interventions

lutetium Lu 177 dotatate 15Everolimus 11Nivolumab 10pembrolizumab 9Temozolomide 9Capecitabine 7cabozantinib 6Sunitinib 6lenvatinib 5lanreotide 4gallium Ga 68 dotatate 4Ipilimumab 4Etoposide 4Carboplatin 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4telotristat ethyl 3pazopanib 3avelumab 3Octreotide 3Magnetic Resonance Spectroscopy 3Injections 3Cyclophosphamide 3Cisplatin 3Bevacizumab 3surufatinib 2sintilimab 2fosbretabulin 2fludarabine 2Specimen Handling 2Sorafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neuroendocrine Tumors × 3-aminopyridine-2-carboxaldehyde thiosemicarbazone × Clear all
NCT05724108 2026-05-13

Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
94 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡